{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:06:20Z","timestamp":1783609580908,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872784"],"award-info":[{"award-number":["81872784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151213"],"award-info":[{"award-number":["82151213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013807","name":"Wuhan University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.intimp.2024.111579","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:07:48Z","timestamp":1706177268000},"page":"111579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity"],"prefix":"10.1016","volume":"128","author":[{"given":"Shengsheng","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Gene","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-800X","authenticated-orcid":false,"given":"Jinbiao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111579_b0005","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.111579_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gt.2016.70","article-title":"Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy","volume":"24","author":"Ilett","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.intimp.2024.111579_b0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111579_b0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111579_b0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.111579_b0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.111579_b0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in Vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2024.111579_b0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","article-title":"Development of oncolytic viruses for cancer therapy","volume":"237","author":"Abd-Aziz","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2024.111579_b0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s11262-017-1488-1","article-title":"Oncolytic viruses: Adenoviruses","volume":"53","author":"Niemann","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.intimp.2024.111579_b0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.intimp.2024.111579_b0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.intimp.2024.111579_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.111579_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Ylosmaki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.intimp.2024.111579_b0070","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy (vol 170, 1109.e1, 2017)","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.111579_b0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotheraoy: Obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2024.111579_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.111579_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002620050512","article-title":"Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy","volume":"47","author":"Li","year":"1998","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2024.111579_b0090","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain FV and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.111579_b0095","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","article-title":"PD-L1 is induced in hepatocytes by viral infection and by interferon-\u03b1 and -\u03b3 and mediates T cell apoptosis","volume":"45","author":"Muehlbauer","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.111579_b0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0976-9668.82318","article-title":"Immunity over inability: The spontaneous regression of cancer","volume":"2","author":"Jessy","year":"2011","journal-title":"Journal of Natural Science, Biology, and Medicine"},{"key":"10.1016\/j.intimp.2024.111579_b0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/0019-509X.82887","article-title":"The role of innate immunity in spontaneous regression of cancer","volume":"48","author":"Thomas","year":"2011","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.intimp.2024.111579_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.111579_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.111579_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: Options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111579_b0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","volume":"588","author":"Kyi","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.intimp.2024.111579_b0130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/21645515.2016.1249551","article-title":"Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors","volume":"13","author":"Silva","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2024.111579_b0135","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1365209","article-title":"PD-L1 inhibitors in the pipeline: Promise and progress","volume":"7","author":"Vanella","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.111579_b0140","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2217\/imt.14.86","article-title":"Current advances in T-cell-based cancer immunotherapy","volume":"6","author":"Wang","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2024.111579_b0145","first-page":"375","article-title":"Immune targeting in breast cancer","volume":"29","author":"Cimino-Mathews","year":"2015","journal-title":"Oncology-New York"},{"key":"10.1016\/j.intimp.2024.111579_b0150","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1158\/1078-0432.CCR-15-1315","article-title":"New strategies in breast cancer: Immunotherapy","volume":"22","author":"Pusztai","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.111579_b0155","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for breast cancer: What are we missing?","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.111579_b0160","doi-asserted-by":"crossref","first-page":"60-+","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.111579_b0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.111579_b0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.virol.2017.12.016","article-title":"Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding","volume":"515","author":"Nidetz","year":"2018","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.intimp.2024.111579_b0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12951-022-01266-3","article-title":"Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy","volume":"20","author":"Chen","year":"2022","journal-title":"J Nanobiotechnology."},{"issue":"16","key":"10.1016\/j.intimp.2024.111579_b0180","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.scib.2022.07.018","article-title":"Antigen self-presenting nanovaccine for cancer immunotherapy","volume":"67","author":"Liang","year":"2022","journal-title":"Sci Bull (beijing)"},{"issue":"1","key":"10.1016\/j.intimp.2024.111579_b0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2017.12.007","article-title":"NKp46 receptor-mediated interferon-\u03b3 production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis","volume":"48","author":"Glasner","year":"2018","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2024.111579_b0190","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ijc.31357","article-title":"IFN-\u03b3-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signalling","volume":"143","author":"Gao","year":"2018","journal-title":"Int J Cancer."},{"key":"10.1016\/j.intimp.2024.111579_b0195","doi-asserted-by":"crossref","first-page":"110346","DOI":"10.1016\/j.intimp.2023.110346","article-title":"Codelivery of triptolide and IFN-\u03b3 to boost antitumor immunity for triple-negative breast cancer","volume":"120","author":"Cai","year":"2023","journal-title":"Int Immunopharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111579_b0200","doi-asserted-by":"crossref","first-page":"902190","DOI":"10.3389\/fonc.2022.902190","article-title":"Oncolytic adenoviral vector-mediated expression of an anti-PD-L1-scFv improves anti-tumoral efficacy in a melanoma mouse model","volume":"20","author":"Vitale","year":"2022","journal-title":"Front Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:14:15Z","timestamp":1761588855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"alternative-id":["S1567576924000973"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111579","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111579"}}